Want to create an interactive transcript for this episode?
Podcast: CME
Episode: GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
Description:
Faculty: Prof. Dr. Johann Bauersachs
Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Contemporary trial data and global registries consistently show that ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event still carry residual risk of cardiovascular death and heart failure hospitalizations. These annual rates have been estimated to exceed 10%–20%, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. This paradox of clinical stability on the surface, yet significant residual risk underneath, creates a critical blind spot in the management of chronic HF...